Neutrolis to Present Early Human Proof-of-Concept Data for Novel NET-Targeting Therapy at ACR 2025
核心洞察
Neutrolis (搜索) will present late-breaking clinical data on NTR-441, an albumin-DNASE1L3 (搜索) fusion protein designed to target Neutrophil Extracellular Traps (搜索) (NETs) in systemic lupus erythematosus (搜索) patients with DNASE1L3 deficiency.
The presentation at ACR Convergence 2025 will showcase early evidence of human proof-of-concept for the company's exDNASE therapeutic platform, marking a significant milestone in NET-targeting therapy development.
Unlike conventional immunosuppressive approaches, NTR-441 aims to provide rapid clinical effects by precisely degrading pathogenic NETs without broadly suppressing immune responses.
Neutrolis (搜索) Inc., a clinical-stage biotechnology company, will present early human proof-of-concept data for its novel Neutrophil Extracellular Trap (NET)-targeting therapy at the American College of Rheumatology (ACR) Convergence 2025. The late-breaking abstract, selected as a podium presentation, describes clinical results for the company's exDNASE therapeutic platform in treating inflammatory disorders.
Clinical Data Presentation at ACR 2025
The presentation, titled "Early Evidence of Proof-of-Concept of an Albumin-DNASE1L3 (搜索) Fusion Protein (NTR-441) for the Rapid Enzymatic Inactivation of NETs in SLE with DNASE1L3-Deficiency," will be delivered by Toby Fox, PhD, Co-founder and Chief Scientific Officer of Neutrolis (搜索). The session is scheduled for Wednesday, October 29, from 8:45 AM to 9:00 AM CT during the Late-Breaking Abstracts session.
"We are excited to present data at ACR Convergence 2025 that validate DNASE1L3 (搜索) as a novel therapeutic approach to degrade and inactivate NETs, a central driver of systemic inflammatory disorders," said Anthony Aiudi, PharmD, Chief Executive Officer of Neutrolis (搜索). "These results mark an important milestone for Neutrolis, underscore the significance of our approach, and highlight our potential to create a new class of transformational, disease-modifying therapies that offer rapid clinical effects in patients without broad immunosuppression."
Novel Mechanism of Action
Neutrolis (搜索) is pioneering a new class of rapid-acting, non-immunosuppressive therapies that directly target NETs, which the company identifies as a root cause of tissue damage and chronic inflammation. Unlike conventional approaches that broadly suppress immune responses, Neutrolis' therapies harness the body's own mechanisms to precisely degrade and inactivate NETs, offering broad potential across inflammatory disorders.
The company's lead program, based on DNASE1L3 (搜索), represents the first therapeutic strategy designed to dismantle pathogenic NETs and prevent their downstream inflammatory effects, restoring immune balance. By targeting this upstream driver of disease, Neutrolis (搜索) aims to deliver transformational, disease-modifying treatments for conditions such as lupus (搜索), rheumatoid arthritis (搜索) and other chronic immune disorders with high unmet need where current therapies remain inadequate.
Therapeutic Potential
The NTR-441 fusion protein specifically targets systemic lupus erythematosus (搜索) (SLE) patients with DNASE1L3 (搜索) deficiency, representing a precision medicine approach to treating this complex autoimmune condition. The therapy's ability to provide rapid enzymatic inactivation of NETs without broad immunosuppression could address significant limitations of current treatment options in inflammatory disorders.
The clinical data being presented at ACR 2025 represents early evidence supporting the therapeutic potential of targeting NETs as a novel approach to treating systemic inflammatory disorders, potentially opening new avenues for patients with conditions that have historically been challenging to treat effectively.